Clinical trial · Interventional
Desmopressin (DDAVP) in Patients With Colorectal Cancer and Rectal Bleeding
Prospective, Open-labelled, Phase II Study, of the Administration of Desmopressin in Patients With Colorectal Cancer, With or Without Metastasis, With Rectal Bleeding, Before Treatment With Surgery and/or Chemotherapy and/or Radiotherapy.
NCT01623206CI-TRIAL-00029235completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of this study is to find the maximum tolerated dose and preliminary efficacy of desmopressin as an haemostatic agent, when is administered to patients with colorectal cancer and rectal bleeding, before specific oncologic treatment with surgery and/or chemotherapy and/or radiotherapy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Rectal Bleeding | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Desmopressin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Desmopressin
- description
- Four dose levels and two dosing schedules with 3 patients in each group.
- interventionNames
- Drug: Desmopressin
Primary outcomes (1)
- measure
- Presence or absence of grade 3 or 4 adverse events related to the study drug, in a maximum of 2 out of 6 patients assessed in each dose level.
- timeFrame
- Up to one week after the administration of the first dose
- description
- A total of 6 groups with 3 patients each, with different dose ranges and dosing schedules will be assessed. The number of patients in each group with grade 3 or 4 adverse events, including clinical or analytical findings, will be determined in order to stablish the maximum tolerated dose.
Secondary outcomes (4)
- measure
- Number of patients with grade 3 or 4 local adverse events
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Patients \> 18 to \< 80 years of age who have signed the informed consent form * Histological diagnosis of rectal adenocarcinoma localized, locally advanced or metastatic * Treatment indication with chemotherapy and/or radiotherapy and/or surgery according to disease stage * Rectal bleeding associated with the primary tumor within 48 hours prior to study entry * Acceptable organ function to be able to participate in the study, performed within 14 days prior to admission; defined by the following parameters: * Electrocardiogram (ECG) without significant clinical abnormalities * Haemoglobin greater than or equal to 8 g/dL * Total leukocyte count greater than or equal to 4.0 x 10\^9/L * Absolute neutrophil count greater than or equal to 1.5 x 10\^9/L * Total platelet count greater to 100.0 x 10\^9/L * Total bilirubin less than or equal to 1.5 times the upper limit of normality (ULN) * Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) less than or equal to 1.5 times upper limit of normality (ULN) * Creatinine clearance greater than 50 ml/min * Performance status (Eastern Cooperative Oncology Group \[ECOG\]) less than or equal to 2 * Patients with childbearing potential should use one of the following contraceptives methods: intrauterine devices, barrier methods and tubal ligation Exclusion Criteria: * Colorectal cancer without bleeding evidences * Pregnancy or lactation * Use of hormonal contraceptives or treatments with sexual hormones in general * Patients with other illnesses not adequately controlled such as congestive heart failure, arterial blood pressure, unstable angina, severe cardiac arrhythmia, thromboembolic disease, diabetes 1 or 2, any hidden coronary disease determined by previous assessments * Psychiatric diseases implying patient incompetence * Known hypersensitivity to desmopressin or vasopressin * Severe von Willebrand disease (vWD)(defined by vWF\<10% Ui/dl) or 2B vWD (defined by increased platelet agregation induced by ristocetin at low concentration) or hemophilia A or B carriers * History of seizures * Renal insufficiency (Creatinine clearance \< 50 ml/min), hyponatremia (serum sodium lower than the lower limit of normality-UNL)or previous history of hyponatremia * Syndrome of inappropriate antidiuretic hormone secretion (SIADH) * Positive serology for hepatitis B, C or known human immunodeficiency virus (HIV) infection * Known liver disease (cirrhosis, liver enzymes greater than or equal to 1.5 times the upper limit of normality or total bilirubin greater than or equal to 1.5 times the upper limit of normality * Active infections wich, according to the investigator judgement, coud interfere with patient safety * Other malignancies, with the exception of basal cell carcinoma, in situ cervical carcinoma, or any other tumour adequately treated and with a disease-free period greater than or equal to 5 years * Patients receiving or having received other investigational drugs 30 days prior to study entry
References
Publications (1)
- DERIVEDIseas S, Roca EL, O'Connor JM, Eleta M, Sanchez-Luceros A, Di Leo D, Tinelli M, Fara ML, Spitzer E, Demarco IA, Ripoll GV, Pifano M, Garona J, Alonso DF. Administration of the vasopressin analog desmopressin for the management of bleeding in rectal cancer patients: results of a phase I/II trial. Invest New Drugs. 2020 Oct;38(5):1580-1587. doi: 10.1007/s10637-020-00914-5. Epub 2020 Mar 12. PMID 32166534